Navigation Links
ERA-EDTA Congress 2011: Late Breaking Clinical Trials II
Date:6/25/2011

PRAGUE, June 25, 2011 /PRNewswire/ --


 

The SHARP-study has shown that lowering LDL cholesterol with ezetimibe/simvastatinleads to a significant reduction in major atherosclerotic events among CKD-patients. Whether it also has a favourable effect on renal disease progression was another of the issues addressed by the SHARP study [abstract no. 2509]. In the ezetimibe/simvastatin group, fewer patients reached the end point "end stage renal disease", but the difference was not significant [p = 0.41].

No improvement in cardiovascular outcome due to optimised treatment quality

Cardiovascular comorbidity in CKD patients is dramatically high. The MASTERPLAN study [abstract no. 2511] aimed to evaluate whether strict implementation of all the current treatment guidelines leads to a better cardiovascular outcome in CKD patients. The primary endpoint was a composite of myocardial infarction, stroke and cardiovascular death. Despite intensified therapy and better lab values it was not possible to significantly improve cardiovascular outcome in the intervention group.

Benefits of tacrolimus therapy with prolonged release in de novo kidney transplant patients

Various immunosuppressive drugs are available, one of these being tacrolimus (Tac). There are tacrolimus products that release their active substance immediately (Tac BID) and others that release it in a prolonged manner (Tac QD). The open-label OSAKA study [abstract no. 2505] compared these two drug forms in various doses. Tac QD led to the achievement of target blood level in more patients within the first few days after transplantation than Tac BID in an identical dose.

Which SHPT therapy should be used?

In the randomised phase IV IMPACT study [abstract no. 2519] 272 hemodialyis patients with seconday hyperparathyreoidism received either paricalcitol or cinacalcet plus low-dose vitamin D. This interim analysis showed that in the paricalcitol group 78% of patients achieved an iPTH reduction of ≥30% and 65% achieved a reduction of ≥50% whilst in the cinacalcet group the figures were 50% and 36% of patients. Concerning side effects, 4 of 69 patients developed hypercalcaemia in the paricalcitol arm, while 27 of 59 patients developed hypocalcemia in the cinacalcet arm.

For further information

http://www.eraedta2011.org/press.html

Bettina Albers
albers@albersconcept.de
+49(0)174-2165629



'/>"/>
SOURCE European Renal Association European Dialysis and Transplant Association (RDA-EDT
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MAP Pharmaceuticals to Present Data on LEVADEX® at the 15th Congress of the International Headache Society
2. Cubist Pharmaceuticals Applauds Congressman Gingrey for Introducing Legislation to Help Fight Superbug Infections
3. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
4. New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinsons Disease And Movement Disorders (MDS)
5. Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatisms Congress
6. U.S. Congressman Michael Capuano to Receive "Lou Gehrig Award" from ALS TDI During Gala Event this November
7. Medical Imaging and Radiation Therapy Personnel Certification Bill Introduced in Congress
8. Oregon Homecare Providers Support Congressional Bill to Repeal Misguided Medicare Bidding Program
9. Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
10. 2011 Retail Clinician Education Congress to Offer Exclusive Accreditation and Networking Opportunities for Retail Healthcare Professionals
11. BioSpecifics Announces Positive XIAPEX® Data Presented at XVI Annual Federation of European Societies for Surgery of the Hand Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016 /PRNewswire/ ... Contamine, Directeur Financier Sanofi, ... santé, publie ses résultats pour le ... du Groupe, Jérôme Contamine, commente les ... et les perspectives pour le reste ...
(Date:4/28/2016)... YORK , April 28, 2016  While ... notably complement the company,s valve repair and stent ... move also places Abbott more firmly into patient ... of the fastest growing device areas, with double-digit ... its recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... April 28, 2016  The blood testing market in ... according to Kalorama Information and The Freedonia Group in ... nucleic acid testing.  The healthcare research firm said that ... developing blood collection stations and in improving testing at ... Information,s report, Blood Testing Market in China ...
Breaking Medicine Technology:
(Date:4/30/2016)... (PRWEB) , ... April 30, 2016 , ... Orlando-based Maximized ... as they go for gold in Rio. Under the care of Maximized Living ... golds! , In an unprecedented showing, Maximized Living is sending the largest contingent of ...
(Date:4/29/2016)... Waltham, MA (PRWEB) , ... April 29, 2016 ... ... 1st, the Two Ten Footwear Foundation, the national charitable foundation serving the footwear ... activities. With 8,000 volunteers representing more than 130 companies across 23 states during ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members ... celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural Health Care ... Cumming), offers a 70% tax credit to individuals and corporations which donate directly to ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Conditions were ideal ... Cove Island Park on Sunday, with sunny skies, a light breeze and temperatures in ... $33,000. , The 5k Run and Walk and 1-mile walk were held ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition ... Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making ...
Breaking Medicine News(10 mins):